Fujisawa
Executive Summary
Japanese pharmaceuticals firm's worldwide sales and profits for the year ended March 31 were 208.6 bil. yen and 6.3 bil. yen, not millions of yen; the dollar translations were correct in "The Pink Sheet" Aug. 28, p. 15. Sales were $ 1.6 bil. and earnings totaled $ 47.6 mil. Also, the calcium channel blocker nilvadipine, launched by the firm in Japan in April as Nivadil, was originally developed by Fujisawa, not Lederle.